Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 21;22(1):237.
doi: 10.1186/s12872-022-02669-8.

Challenges faced by patients with dyslipidemia and systemic arterial hypertension in Brazil: a design of the patient journey

Jose Rocha Faria-Neto  1 , Carlos Yarleque  2 , Luiz Fernando Vieira  3 , Eliane Naomi Sakane  3 , Raul D Santos  4   5
Affiliations
Review

Challenges faced by patients with dyslipidemia and systemic arterial hypertension in Brazil: a design of the patient journey

Jose Rocha Faria-Neto et al. BMC Cardiovasc Disord. .

Abstract

Background and objective: Non-communicable diseases like systemic arterial hypertension (SAH) and dyslipidemia are poorly studied in terms of patient journey aspects. This semi-systematic review provides evidence synthesis for the management of SAH and dyslipidemia in Brazil and also discusses challenges faced by patients at the local level along with a suggested care approach by local experts.

Methods: A semi-systematic review using both structured literature databases (Embase and Medline) and unstructured scientific records (WHO, IPD, MOH and Google) on hypertension and dyslipidemia in the English language from 2010 to 2019 was performed by reviewers. After two-level screening based on pre-defined criteria, patient journey touchpoints and prevalence information were extracted from the included articles. Data gaps were bridged through the insights of local experts.

Results: Prevalence of hypertension and dyslipidemia in Brazil were 23% and 40.8%, respectively. Awareness of dyslipidemia was found in a larger proportion (58.1%) than in SAH (22.2%). Similarly, screening for hypertension (97%) and dyslipidemia (55.4%) were found to be effective, while treatment was (62.9%) and (30.0%) for hypertension and dyslipidemia, respectively.

Conclusion: There were important gaps on patient awareness and treatment of dyslipidemia and hypertension. Limited patient education, regional disease distribution, and treatment allocation, along with limited resources for diagnosis and treatment are the key challenges.

Keywords: Diagnosis; Dyslipidemia; Patient journey; Prevalence; Systemic arterial hypertension; Treatment.

PubMed Disclaimer

Conflict of interest statement

JRF received honoraria for consulting, speaker, or research activities from Aché, Astra Zeneca, Amgen, EMS, Merck, MSD, Novo-Nordisk, Pfizer, PTC therapeutics, and Sanofi/Regeneron. He is a recipient of a scholarship from the Conselho Nacional de Pesquisa e Desenvolvimento Tecnologico (CNPq) process # 314145/2018-4. RDS received honoraria for consulting, speaker, or research activities from Abbott, Aché, Astra Zeneca, Amgen, EMS, Esperion, GETZ pharma, Kowa, Libbs, Merck, MSD, Novo-Nordisk, Novartis, Pfizer, PTC Therapeutics, Roche and Sanofi/Regeneron. He is a recipient of a scholarship from the Conselho Nacional de Pesquisa e Desenvolvimento Tecnologico (CNPq) process # 303734/2018-3, Brazil. LFV, ENS and CRY are employees of Pfizer Upjohn.

Figures

Fig. 1
Fig. 1
PRISMA flow diagram for systemic arterial hypertension in Brazil
Fig. 2
Fig. 2
PRISMA flow diagram for dyslipidemia in Brazil
Fig. 3
Fig. 3
Summary of findings from the included studies on hypertension and dyslipidemia in Brazil. *Weighted average; aPeer-reviewed publication; bScientific literature + expert opinion; cExpert opinion only. Here navy blue, red, light green, and dark green colored doughnuts are indicative of percentage ranges ≤ 25%, 25–50%, 50–75%, and ≥ 75%, respectively. Health literacy: 68%a
Fig. 4
Fig. 4
Key patient journey challenges and proposed solutions for patients with cardiovascular diseases in Brazil
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases...). Accessed 29 Jan 2021.
    1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139:e56–e528. doi: 10.1161/CIR.0000000000000659. - DOI - PubMed
    1. Radovanovic CAT, dos Santos LA, de Carvalho MDB, Marcon SS. Arterial hypertension and other risk factors associated with cardiovascular diseases among adults. Rev Lat Am Enfermagem. 2014;22:547–553. doi: 10.1590/0104-1169.3345.2450. - DOI - PMC - PubMed
    1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–223. doi: 10.1016/S0140-6736(05)17741-1. - DOI - PubMed
    1. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–2260. doi: 10.1016/S0140-6736(12)61766-8. - DOI - PMC - PubMed

Publication types